当前位置:Public Access >页面
Chinese/English
A clinical trial of combined PARP inhibition, androgen receptor‑targeted therapy, and PD‑1 blockade in patients with metastatic castration‑resistant prostate cancer
Filter Options
Patient No. Patient Name Patient Gender
Sitting Education Date of enrollment FromTo
       More Options
Patient No Gender Date of enrollment Sitting Creater Operate
NO participants recorded。